Genfit reported first-half 2025 results alongside a decisive R&D reset: discontinuation of VS-01 in acute-on-chronic liver failure after a serious adverse event, refocusing that asset on urea cycle disorder, and extending cash runway beyond 2028. The company posted €35.7 million in revenues and other income, including €26.5 million from a pricing and reimbursement milestone tied to Iqirvo in three major European markets, and €6.9 million in royalties from partner Ipsen’s commercialization in primary biliary cholangitis. Cash stood at €107.5 million on June 30, excluding the milestone received in July, supported by a royalty financing closed in March. The quarter captures a company leaning into a royalty- and milestone-driven model while concentrating internal spend on a diversified ACLF pipeline and oncology, with near-term data from G1090N in ACLF and GNS561 in cholangiocarcinoma expected by year-end.
The strategic question is whether pruning a risky ACLF program now, while doubling down on multiple mechanistic shots on goal and non-dilutive financing, creates the right balance between capital efficiency and clinical momentum. For a mid-cap with commercial exposure primarily via a partner, the answer hinges on two levers: Ipsen’s execution with Iqirvo and Genfit’s ability to translate early ACLF signals into tangible de-risking milestones that can attract co-funding or partnerships.
Commercially, the PBC market is in flux. Ipsen reported accelerating Iqirvo sales in the U.S. and Europe, and September’s FDA-requested withdrawal of Ocaliva in the U.S. removes the most entrenched branded competitor. That shift could simplify access negotiations and prescribing patterns in the near term, but raises a fresh bar for evidence generation. Payers will scrutinize durability, safety, and real-world outcomes as volumes move, and hepatologists will expect clear differentiation in complex second-line populations. Medical Affairs teams should prepare for intensified evidence needs, including pragmatic RWE, adherence and safety monitoring frameworks, and potential subgroup analyses to underwrite payer confidence. If elafibranor’s positive phase 2 readout in primary sclerosing cholangitis converts into a second indication, the royalty stream and milestone cadence could expand materially, further strengthening Genfit’s non-dilutive funding base and widening Ipsen’s cholestatic disease franchise.
On the development side, Genfit’s pivot clarifies resource allocation in ACLF: G1090N appears to be the next readout, with safety and early efficacy markers in healthy volunteers guiding a 2026 proof-of-concept. Additional assets (SRT-015, CLM-022, VS-02-HE) stagger future catalysts, but the immediate imperative is to generate human data that validates the mechanism and informs trial design in an indication historically plagued by heterogeneity and endpoint ambiguity. The acquisition of full IP rights to GNS561 tightens control over a potential second pillar in oncology; upcoming phase 1b data in cholangiocarcinoma will indicate whether the program merits broader investment or partnering.
Financially, royalty financing is becoming a standard bridge for European biotechs seeking to extend runway without equity dilution, but it concentrates risk on partnered commercial performance and sales thresholds. Genfit’s H1 net loss and higher financial charges reflect that trade-off. Governance transitions, including new leadership in clinical and scientific roles, add execution sensitivity at a moment when clinical prioritization and field evidence generation must be tightly synchronized.
The next six to twelve months will test whether Iqirvo’s tailwinds in PBC, potentially amplified by competitor exit and PSC optionality, can underwrite a more ambitious ACLF agenda. The open question for competitors and potential partners: will Genfit use its extended runway to consolidate an ACLF leadership position through inorganic deals or co-development, or will it wait for the first human signals to reset valuations and terms?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
